Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | Director · Chief Executive Officer | October 06, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Artiva Biotherapeutics, Inc.
Report date October 06, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,519,606 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Sale · Disposed 23,463 · Balance 1,519,606 F1: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026. F2: The weighted average sale price for the transaction reported was $7.1977, and the range of prices were between $6.92 and $7.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026.
F2: The weighted average sale price for the transaction reported was $7.1977, and the range of prices were between $6.92 and $7.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 7, 2026 20:02 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 23,463 | $7.20 | $168,879.64 |
DisclosureSEC source: 0001193125-26-416953 · ownership.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,519,606 F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026. F2 · price: The weighted average sale price for the transaction reported was $7.1977, and the range of prices were between $6.92 and $7.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 20:01 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 61,696 | $6.84 | $421,827.89 |
DisclosureSEC source: 0001193125-26-415527 · ownership.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,543,069 F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 20:44 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantEmployee Stock Option (Right to Buy) · Derivative | 315,000 | $0.00 Strike: $8.91 | $0.00 |
DisclosureSEC source: 0001193125-26-392025 · ownership.xml · derivative · entry 2 Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,000 Underlying: Common Stock · 315,000 shares Expires 2036-09-14 F2 · derivative.exercise_date: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period. Read SEC document |
| September 15, 2026 Filed Sep 15, 2026 20:44 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-392025 · ownership.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,604,765 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| September 10, 2026 Filed Sep 15, 2026 00:07 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantEmployee Stock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0001193125-26-391012 · ownership.xml · derivative · entry 2 Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2036-09-09 F2 · derivative.exercise_date: Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period. Read SEC document |
| September 10, 2026 Filed Sep 15, 2026 00:07 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-391012 · ownership.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,494,765 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 20:02 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 23,429 | $10.92 | $255,746.28 |
DisclosureSEC source: 0001193125-26-386431 · ownership.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,449,765 F1 · kind: The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026. F2 · price: The weighted average sale price for the transaction reported was $10.9158, and the range of prices were between $10.72 and $11.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 03, 2026 Filed Sep 4, 2026 20:02 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 61,888 | $11.16 | $690,391.58 |
DisclosureSEC source: 0001193125-26-383618 · ownership.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,473,194 F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0270 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 19, 2026 Filed May 20, 2026 01:50 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 27,116 | $9.01 | $244,252.79 |
DisclosureSEC source: 0001193125-26-231506 · ownership.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,535,082 F1 · shares: The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The weighted average sale price for the transaction reported was $9.0077, and the range of prices were between $8.7383 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 23:48 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 14,600 | $4.00 | $58,400.00 |
DisclosureSEC source: 0001193125-26-057667 · ownership.xml · nonDerivative · entry 2 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,562,198 F2 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 23:48 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 366,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057667 · ownership.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,576,798 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 02:19 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 3,187 | $6.00 | $19,122.00 |
DisclosureSEC source: 0001193125-25-319696 · ownership.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,209,948 F1 · shares: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:19 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 319,331 | Not disclosed Strike: $12.00 | Not disclosed |
DisclosureSEC source: 0001193125-25-317980 · ownership.xml · derivative · entry 7 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 319,331 shares Expires 2034-07-17 F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. F6 · derivative.exercise_date: 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:19 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 113,999 | Not disclosed Strike: $13.47 | Not disclosed |
DisclosureSEC source: 0001193125-25-317980 · ownership.xml · derivative · entry 6 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,999 shares Expires 2034-05-01 F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. F6 · derivative.exercise_date: 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:19 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 26,450 | Not disclosed Strike: $5.18 | Not disclosed |
DisclosureSEC source: 0001193125-25-317980 · ownership.xml · derivative · entry 5 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,450 shares Expires 2034-01-23 F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. F5 · derivative.exercise_date: Vesting is monthly over a 48-month period starting January 1, 2024 in equal monthly amounts. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:19 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 257,319 | Not disclosed Strike: $5.01 | Not disclosed |
DisclosureSEC source: 0001193125-25-317980 · ownership.xml · derivative · entry 4 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257,319 shares Expires 2030-12-17 F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. F4 · derivative.exercise_date: 25% of the shares vest on January 1, 2022, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:19 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 51,463 | Not disclosed Strike: $5.01 | Not disclosed |
DisclosureSEC source: 0001193125-25-317980 · ownership.xml · derivative · entry 3 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,463 shares Expires 2030-12-17 F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. F3 · derivative.exercise_date: 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:19 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 100,577 | Not disclosed Strike: $5.01 | Not disclosed |
DisclosureSEC source: 0001193125-25-317980 · ownership.xml · derivative · entry 2 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,577 shares Expires 2031-02-23 F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. F3 · derivative.exercise_date: 25% of the shares vested on February 22, 2022, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| December 12, 2025 Filed Dec 13, 2025 00:19 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 869,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-317980 · ownership.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,213,135 F1 · shares: Represents restricted stock units award granted under the Issuer's 2024 Equity Incentive Plan ("RSUs"). F2 · price: On December 12, 2025, the Issuer cancelled, pursuant to an option exchange, the options listed in Table II. In exchange for the cancelled options, the Reporting Person received the RSUs reported in Table I. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 01:37 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 6,375 | $3.38 | $21,522.00 |
DisclosureSEC source: 0001193125-25-285004 · ownership.xml · nonDerivative · entry 2 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 343,999 F2 · kind: The reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024. F3 · price: The weighted average sale price for the transaction reported was $3.376, and the range of prices were between $3.19 and $3.53. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 01:37 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 6,347 | $3.25 | $20,627.75 |
DisclosureSEC source: 0001193125-25-285004 · ownership.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 350,374 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| October 17, 2025 Filed Oct 18, 2025 00:44 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 25,500 | $6.00 | $153,000.00 |
DisclosureSEC source: 0001909362-25-000004 · form4-10182025_121003.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 356,721 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 00:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 4,472 | $2.75 | $12,298.00 |
DisclosureSEC source: 0001415889-25-022224 · form4-08182025_080810.xml · nonDerivative · entry 3 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 382,221 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 00:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | SaleCommon Stock | 25,500 | $2.73 | $69,579.30 |
DisclosureSEC source: 0001415889-25-022224 · form4-08182025_080810.xml · nonDerivative · entry 2 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 386,693 F2 · shares: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 23, 2024, to satisfy income tax obligations associated with the vesting of restricted stock unit awards. F3 · price: The weighted average sale price for the transaction reported was $2.7286, and the range of prices were between $2.60 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 15, 2025 Filed Aug 19, 2025 00:15 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | Tax withholdingCommon Stock | 4,472 | $2.13 | $9,525.36 |
DisclosureSEC source: 0001415889-25-022224 · form4-08182025_080810.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 412,193 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:35 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007431 · form4-03072025_090355.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,665 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. F2 · balance_after: Reflects reduction in the number of shares subject to the RSU granted on July 22, 2024 from 228,905 shares to 216,665 shares. The equity award was originally calculated based on the maximum offering size of the Company's initial public offering (IPO) and such award was subsequently adjusted following the partial exercise of the underwriters option to purchase additional shares in connection with the IPO. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 00:18 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantCommon Stock | 228,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-019905 · form4-07232024_120741.xml · nonDerivative · entry 1 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,905 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan. Read SEC document |
| July 18, 2024 Filed Jul 23, 2024 00:18 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantEmployee Stock Option (Right to Buy) · Derivative | 343,811 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001415889-24-019905 · form4-07232024_120741.xml · derivative · entry 2 Aslan Fred · CIK 0001909362 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,811 Underlying: Common Stock · 343,811 shares Expires 2034-07-17 F2 · derivative.exercise_date: 25% of the shares will vest on July 19, 2025, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.